News & Investoren

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Jahr: 2020

Neue Studie im Journal of the National Cancer Institute zeigt, dass Epi proColon(R) der bevorzugte Test der zahlreichen Patienten ist, die nicht bereit sind, am Darmkrebs-Screening per FIT oder Darmspiegelung teilzunehmen

DGAP-News: Epigenomics AG / Schlagwort(e): Studienergebnisse/Studie10.08.2020 / 08:00 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Neue Studie im Journal of the National Cancer Institute zeigt, dass Epi proColon(R) der bevorzugte Test der zahlreichen Patienten ist, die nicht bereit sind, am Darmkrebs-Screening per FIT oder Darmspiegelung teilzunehmen Im Rahmen der primären Basisfallanalyse […]

Read more

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG10.08.2020 / 10:09 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]

Read more

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG06.08.2020 / 11:34 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]

Read more

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG31.07.2020 / 09:01 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]

Read more

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG31.07.2020 / 11:35 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]

Read more

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG29.07.2020 / 15:15 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]

Read more